Recommendations regarding changes in medication are evaluated by reassessing the medication use as described above.
Further beneficial effects for quality of life, coping ability and adherence to medication are evaluated.
In the third step the newly initiated medication is evaluated to ensure all changes are intentional and changes in the pharmacotherapy are documented.
In the single-dose pain assessment phase of the study, the analgesic efficacy of a single dose of study medication was evaluated.
The association between BUA levels and serum levels of the above items, along with the type of received antipsychotic medication, was evaluated.
Additionally, completeness on reported medication was evaluated including the medication name, the dose per intake, the number of doses per day, and the number of days that the medication was taken during the previous 4 weeks.
At the beginning of the second face-to-face counselling session (FC2; day 8, duration 40 minutes), the use of the study medication is evaluated and possible side effects are discussed.
The relationship between VEGF concentration in serum (response variable) through time (basic model) and the covariates observed or measured along with the response (as additional random effects), such as biochemical and clinical variables and medication, was evaluated.
One of the most widely used models is the Health Belief Model HBMM) which is a theoretical framework postulating that adherence decisions are based on implicit cost-benefit analyses, where the extent to which a patient views the necessity of medication is evaluated against concern about potential side effects [ 35].
The electrocardiogram (ECG) and laboratory measurements including hematology and glycosylated hemoglobin (HbA1c) were performed at enrollment and at week 12. Adherence to the study medication was evaluated by measuring the difference between the dosage dispensed and the tablets returned at each scheduled visit.
